TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1774431
Drug: 5-HT uptake
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT uptake inhibitors (amitriptyline, clovoxamine, fluvoxamine) for 28 days
Study: 1774431
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with trazodone or maprotiline (weak inhibitors of platelet 5-HT uptake)
Study: 31665578
Drug: Gilteritinib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gilteritinib (120 mg per day)
Study: 23478060
Drug: R-BEAM (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-BEAM (rituximab 375 mg/m² on days -19 and -12, plus carmustine 300 mg/m², etoposide 100 mg/m² twice daily, cytarabine 100 mg/m² twice daily, and melphalan 140 mg/m²)
Study: 23478060
Drug: B-BEAM (iodine-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-BEAM (iodine-131 tositumomab dosimetric dose of 5 mCi on day -19 and therapeutic dose of 0.75 Gy on day -12, plus carmustine 300 mg/m², etoposide 100 mg/m² twice daily, cytarabine 100 mg/m² twice daily, and melphalan 140 mg/m²)
Study: 23964468
Drug: Naturopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturopathic treatment
Study: 23964468
Drug: Orthopaedic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthopaedic treatment
Study: 19583076
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% (3 mg/kg) + Nitroglycerin (200 microg)
Study: 17241505
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 microg kg(‐1) bolus 10 min before induction plus 0.5 microg kg(‐1) h(‐1) infusions during maintenance
Study: 11699169
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate (62.5 mg/kg) with promethazine (12.5 mg)
Study: 9224438
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg subcutaneous bolus)
Study: 9224438
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (800 mg orally)
Study: 9224438
Drug: L‐Dopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐Dopa (500 mg orally)
Study: 9224438
Drug: GH‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH‐releasing hormone (GH‐RH 1 microgram/kg body weight i.v. bolus)
Study: 8118565
Drug: Cefaclor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (500 mg) twice daily for 10 days
Study: 8118565
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg) three times daily for 10 days
Study: 3729164
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg twice daily for 3 days)
Study: 25120324
Drug: Early prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early prophylactic (EP) pulmonary surfactant therapy
Study: 25120324
Drug: Late selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late selective (LS) pulmonary surfactant therapy
Study: 18552688
Drug: Pyridoxalated hemoglobin
Normalized name: Pyridoxalated hemoglobin polyoxyethylene
DrugBank: Hemoximer (DB17600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxalated hemoglobin polyoxyethylene (PHP) at 0.25 mL/kg/hr (20 mg/kg/hr)
Study: 15780531
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - continuous combined 0.625 mg conjugated equine estrogen plus 2.5 mg/d medoxyprogesterone
Study: 12413000
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) - 2 sessions of 10 minutes of training at 30% of PImax, daily for 4 weeks
Study: 12413000
Drug: Respiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory Muscle Stretch Gymnastics (RMSG) - 3 sessions of 5 RMSG patterns 4 times each, daily for 4 weeks
Study: 10530772
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg orally, twice daily
Study: 1746970
Drug: HCFU administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCFU administration (300-600 mg/day x 12 weeks or more)
Study: 1746970
Drug: Radical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical therapy only (Control Group A)
Study: 6180562
Drug: Flecainide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (400 mg daily)
Study: 30566416
Drug: L-Methylfolate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Methylfolate (15 mg)
Study: 9689270
Drug: Granisetron 2
Normalized name: granisetron 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2 mg
Study: 9689270
Drug: Granisetron 4
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 4 mg
Study: 9666879
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg orally once daily for 12 months)
Study: 9666879
Drug: Ketoconazole (200-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200-600 mg orally daily)
Study: 31325468
Drug: Generic direct-acting
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic direct-acting antivirals (DAAs) with sofosbuvir + ledipasvir ± ribavirin or sofosbuvir + daclatasvir ± ribavirin
Study: 31325468
Drug: Generic direct-acting
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic direct-acting antivirals (DAAs)
Study: 25952121
Drug: Combined manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined manual acupuncture and massage therapy (MAMT)
Study: 25952121
Drug: Manual acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual acupuncture therapy (MAT)
Study: 24364801
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation (BA) treatment for depression
Study: 21515198
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy plus either switch to another selective serotonin reuptake inhibitor (SSRI) or switch to venlafaxine
Study: 21515198
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to another selective serotonin reuptake inhibitor (SSRI)
Study: 11049707
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose gentamicin (4.5 mg/kg) plus metronidazole (500 mg) preoperatively
Study: 11049707
Drug: Multiple standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple standard dose gentamicin (1.5 mg/kg) plus metronidazole (500 mg) preoperatively and every 8h for 24h postoperatively
Study: 8776678
Drug: 0.72 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.72 g/kg (0.9 ml/kg) of ethanol
Study: 1458013
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GH plus oxandrolone
Study: 1458013
Drug: GH alone
Normalized name: LINER,SECURELY YOURS,PAPER PAK #GH-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH alone and combination therapy
Study: 3881209
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 micrograms/kg bolus followed by 5 micrograms h‐1 kg‐1 infusion)
Study: 3881209
Drug: Saline (corresponding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (corresponding volume bolus followed by saline infusion)
Study: 31101977
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (two unlabeled soft capsules containing 200 μg folic acid each, for 3 months)
Study: 24909468
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg and Metoclopramide 10 mg (DM group)
Study: 24909468
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg (MO group)
Study: 24909468
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg (DO group)
Study: 20157135
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d
Study: 17343543
Drug: Oral misoprostol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral misoprostol, 50 microg every 4 h for up to three doses
Study: 2667758
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 mg bid for 2 days
Study: 335924
Drug: Albuterol (170
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (170 micrograms)
Study: 25487027
Drug: Preservative-free sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free sodium hyaluronate 0.1% and preservative-free fluorometholone 0.1% eyedrops, 4 times a day in the first month and twice a day in the second month.
Study: 25487027
Drug: Preserved sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preserved sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops, 4 times a day in the first month and twice a day in the second month.
Study: 24070809
Drug: VEGF inhibition
Normalized name: Vegf receptor 2 kinase inhibitor i
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF inhibition (anti-VEGF therapy)
Study: 21651869
Drug: Sevoflurane inhalation
Normalized name: Sevoflurane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane inhalation anesthesia
Study: 16772718
Drug: TOTO regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOTO regimen (4 years alternating treatment and observation, n = 30)
Study: 16772718
Drug: TTOO regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTOO regimen (2 years treatment followed by 2 years observation, n = 28)
Study: 11198661
Drug: i.m. vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. vaccine
Study: 9056064
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline (375 mg)
Study: 8116453
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 100 mg of bisaramil
Study: 8116453
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of 35 mg of bisaramil
Study: 10081852
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (40 mg)
Study: 3086575
Drug: Thiotepa (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiotepa (60 mg)
Study: 22180582
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine (1.0 mcg/kg/min)
Study: 22180582
Drug: Alcohol (targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (targeted breathalyzer of 40 mg% and 80 mg%)
Study: 19878041
Drug: Acidic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidic agents (citrate buffer solution, pineapple juice, green mango juice)
Study: 19878041
Drug: Acidic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidic agents
Study: 17712585
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml orange juice and 250 ml blackcurrant juice
Study: 17712585
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg vitamin E
Study: 17712585
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml orange juice and 250 ml blackcurrant juice and 15 mg vitamin E
Study: 10464824
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 0.4 mg kg‐1
Study: 2702016
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg nocte) - Long-term treatment
Study: 2702016
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg nocte) - Seasonal treatment
Study: 2702016
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg nocte) - Multicenter trial
Study: 27483410
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) + etanercept (ETN) combination therapy
Study: 27483410
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) + sulfasalazine (SSZ) + hydroxychloroquine (HCQ) triple therapy
Study: 21430116
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (800 μg daily for 3 years)
Study: 19880456
Drug: Screening linked
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening linked to treatment options via referral and follow-up
Study: 9707027
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (chemo)
Study: 9707027
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and total body irradiation (chemo + TBI)
Study: 3349312
Drug: Wedge resection/segmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wedge resection/segmental phenolization combination treatment (WR/SP)
Study: 26286872
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.5 mg/kg)
Study: 26286872
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate syrup (50 mg/kg)
Study: 19778920
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment of non-IRA (CR group)
Study: 8841153
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (25 mg/16 hr) during sauna session
Study: 7884019
Drug: Fluvoxamine 150
Normalized name: fluvoxaMINE 150 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 150 mg per day
Study: 6839004
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg single oral dose)
Study: 6839004
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg single oral dose)
Study: 31558376
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ivermectin 200 μg/kg
Study: 31558376
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of ivermectin 200 μg/kg (given on days 1, 2, 15, and 16)
Study: 26854246
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg daily)
Study: 24280344
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg/day) for 6 months
Study: 20956902
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg midazolam with 0.5% hyperbaric bupivacaine
Study: 17959979
Drug: Morphine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine IV PCA
Study: 16277588
Drug: Mechanical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical and chemical oral cleansing using povidone-iodine
Study: 16277588
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral health care (POHC) administered by dental hygienists once a week for 24 months
Study: 16277588
Drug: POHC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: POHC treatment for 6 months in the winter season
Study: 16406170
Drug: HPIV3cp45 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPIV3cp45 vaccine
Study: 10828084
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose GH (1 U daily)
Study: 10828084
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose GH (2 U daily)
Study: 10828084
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose GH (after 12 months)
Study: 8657857
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy with relaxation therapy and autogenic training
Study: 8657857
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy with relaxation therapy and autogenic training
Study: 1505610
Drug: 16-hour nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-hour nicotine patch releasing 15 mg nicotine applied daily for 16 h over 12 weeks
Study: 6412224
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg three times daily
Study: 6345370
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg three times daily
Study: 29438562
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (n = 1002)
Study: 29438562
Drug: Td vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td vaccine (n = 328)
Study: 26305442
Drug: Classroom Communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom Communication Resource (CCR) intervention administered to 97 participants in the experimental group.
Study: 20118780
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin threshold of 7.0 g/dL)
Study: 20118780
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin threshold of 9.5 g/dL)
Study: 12401733
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU vitamin E daily
Study: 10064663
Drug: Cisapride (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.2 mg/kg 4 times daily for 2 weeks)
Study: 29273477
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (Hb < 7.5 g/dL)
Study: 29273477
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (Hb < 9.5 g/dL intraoperatively or postoperatively in ICU; Hb < 8.5 g/dL on the ward)
Study: 25493193
Drug: L-tug lycosome
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tug lycosome formulation of dark chocolate (30 g daily)
Study: 25493193
Drug: Regular dark
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dark chocolate (30 g daily)
Study: 25493193
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate with 7 mg of lycopene
Study: 15206992
Drug: Tetracycline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (500 mg 12 hourly for 7 days)
Study: 11507213
Drug: ALVAC-HIV recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV recombinant canarypox vaccines
Study: 9674400
Drug: Rapidly shaking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapidly shaking and pinching the skin during lidocaine injection
Study: 8018904
Drug: MCNU-VMP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCNU-VMP therapy
Study: 8018904
Drug: VMP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMP therapy
Study: 162677
Drug: Viloxazine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine (150 mg daily)
Study: 162677
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 mg daily)
Study: 29126292
Drug: ZVIN (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZVIN (4 doses)
Study: 28954982
Drug: Non-administration (control)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-administration (control)
Study: 15608541
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluoxetine and cognitive-behavioral therapy
Study: 1534422
Drug: Cefixime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (400 mg or 800 mg single oral dose)
Study: 1534422
Drug: Ceftriaxone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (250 mg single intramuscular dose)
Study: 6378988
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg q.i.d. per os)
Study: 6378988
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg b.i.d. per os)
Study: 28948440
Drug: Intrauterine hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine hCG infusion prior to embryo transfer (ET)
Study: 28948440
Drug: No hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hCG infusion prior to embryo transfer (ET)
Study: 26681752
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (atorvastatin/niacin)